Table 5.

Distribution of Ki-67 index (all layers) in patients by smoking status and treatment at baseline, 3 mo, and difference from baseline to 3 mo (n = 200)

Smoking statusTreatmentVariablenMeanSDMinimumMedianMaximumP*
FormerCCX, dose 0Baseline112.902.360.502.698.630.55
3 mo83.854.570.171.3111.06
Difference81.045.43−8.190.559.88
CCX, dose +1Baseline104.897.680.931.8726.240.38
3 mo72.472.750.101.628.18
Difference7−3.8510.13−25.6−1.796.32
PlaceboBaseline183.885.770.081.5023.810.95
3 mo132.802.380.142.237.45
Difference13−1.236.16−20.10.036.89
CurrentCCX, dose 0Baseline306.627.370.384.1630.890.97
3 mo256.484.890.255.4616.23
Difference250.065.22−11.5−0.6812.97
CCX, dose +1Baseline506.034.840.354.5923.660.27
3 mo296.765.880.005.4319.82
Difference28−1.106.91−13.5−1.7114.12
PlaceboBaseline806.056.180.004.6532.130.89
3 mo447.667.100.006.1538.10
Difference440.158.58−26.4−0.1534.42

NOTE: One patient did not have a baseline Ki-67 reading due to inadequate tissue.

  • *Wilcoxon signed-rank test comparing modulation of Ki-67 index within each subgroup.